LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $7.23B
- P/E (TTM)
- –
- Dividend yield
- –
Legend Biotech Corp revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | – | – | – | – | – | $75.68M | $57.26M | $48.10M | – | – |
| China | – | $320.00K | $179.00K | $328.00K | $3.42M | $0 | $3.00K | $1.03M | – | – |
| United States | – | $144.34M | $35.16M | $50.00M | $65.40M | $75.00M | $59.98M | – | – | – |
| Other | – | – | – | $75.00K | $0 | $0 | – | – | – | – |
From the segment and revenue-disaggregation notes of Legend Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.